


# Executive Oncology Overview




150


Total\_Patients





86


Late\_Stage\_Patients





**Study\_Centre** 


All 

**Age\_Group** 

All 



**Molecular\_Subtype** 



All 




Molecular_Subtype	I	II	III	IV	Total
HER2+	6	6	6	6	24
Luminal A	7	12	22	17	58
Luminal B	5	12	10	14	41
Triple Negative	7	9	6	5	27
Total	25	39	44	42	150

Subtype Proportion by Stage


Molecular\_Subtype ● HER2+ ● Luminal A ● Luminal B ● Triple Negative




Total\_Patients by Age\_Group




Parity vs Subtype




Age vs Stage



Breastfeeding vs Stage





### Summary Table

Study_Centre	Total_Patients	Late_Stage_Patients	Late_Stage_%
Centre A	55	37	67.3%
Centre B	46	23	50.0%
Centre C	49	26	53.1%
Total	150	86	57.3%

